Loading...
XPAR
IPH
Market cap204mUSD
Jun 02, Last price  
1.94EUR
1D
-1.52%
1Q
-2.02%
Jan 2017
-86.72%
IPO
-59.33%
Name

Innate Pharma SA

Chart & Performance

D1W1MN
P/E
—
P/S
3.44
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.48%
Rev. gr., 5y
-8.27%
Revenues
52m
+4.56%
1,300,0006,195,00014,290,00012,924,0007,716,0004,320,00011,740,00010,377,00012,469,000907,00017,906,00056,160,00032,631,00079,892,00068,973,00056,833,00012,112,00049,639,00051,901,000
Net income
-8m
L-92.36%
-6,129,000-6,042,000-8,918,000-9,852,000-14,626,000-13,658,000-6,980,000-3,199,000-2,892,000-19,647,000-6,706,00012,640,000-48,385,0003,049,000-20,965,000-70,747,000-59,136,000-99,103,000-7,570,000
CFO
-33m
L+69.98%
-7,249,000360,000-9,282,000-14,741,000-5,936,000-13,449,00012,986,000-10,475,000-10,967,000-18,134,000207,912,000-36,851,000-48,060,000-32,531,00034,924,000-51,807,000-58,457,000-19,154,000-32,558,000

Profile

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
URL
https://www.innate-pharma.com/
IPO date
Oct 31, 2006
Employees
211
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
51,901
4.56%
49,639
309.83%
Cost of revenue
123,792
125,762
Unusual Expense (Income)
NOPBT
(71,891)
(76,123)
NOPBT Margin
Operating Taxes
41,131
Tax Rate
NOPAT
(71,891)
(117,254)
Net income
(7,570)
-92.36%
(99,103)
67.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
395
198
BB yield
-0.19%
-0.08%
Debt
Debt current
8,936
2,102
Long-term debt
31,792
42,208
Deferred revenue
7,921
Other long-term liabilities
61,698
55,736
Net debt
(61,524)
(92,294)
Cash flow
Cash from operating activities
(32,558)
(19,154)
CAPEX
(351)
(1,122)
Cash from investing activities
20,631
1,877
Cash from financing activities
(1,966)
(1,828)
FCF
(101,547)
(115,622)
Balance
Cash
92,456
101,485
Long term investments
9,796
35,119
Excess cash
99,657
134,122
Stockholders' equity
(332,354)
(325,486)
Invested Capital
485,846
479,567
ROIC
ROCE
EV
Common stock shares outstanding
80,453
79,640
Price
2.62
-20.36%
3.29
-26.03%
Market cap
210,788
-19.55%
262,015
-25.94%
EV
149,264
169,721
EBITDA
(66,800)
(30,718)
EV/EBITDA
Interest
640
5,321
Interest/NOPBT